Kiora Pharmaceuticals Inc $KPRX

What the company doesAI summary of filing

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for retinal diseases. The company's lead program, KIO-301, is a small-molecule photoswitch candidate in Phase 2 development for retinitis pigmentosa and other inherited retinal diseases; it completed a Phase 1b trial in September 2023 showing improvements in vision. KIO-104, a DHODH inhibitor formulated for intravitreal injection, is in Phase 2 development for diabetic macular edema and posterior non-infectious uveitis, with enrollment currently ongoing in the KLARITY trial. KIO-101, a topical formulation of the same compound as KIO-104, completed Phase 1b testing for ocular surface inflammation and the company is pursuing strategic partnerships for its development. Kiora has partnered KIO-301 globally (except certain Asian countries) with Théa Open Innovation and granted Senju an option for development and commercialization rights in Japan and China; the company is pre-revenue and generates income through upfront payments and milestone achievements from these partnerships. [10-K 2026-03-25]

Segments: KIO-301 (retinitis pigmentosa and inherited retinal diseases), KIO-104 (diabetic macular edema and posterior non-infectious uveitis), KIO-101 (ocular manifestations of autoimmune diseases)